Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer

P.J. Slavish(St. Jude Children's Research Hospital), Philip M. Potter, Nagakumar Bharatham(University of Trans-Disciplinary Health Sciences and Technology), Geoffrey Neale(St. Jude Children's Research Hospital), Sourav Das(St. Jude Children's Research Hospital), Vincent A. Boyd(St. Jude Children's Research Hospital), Martine F. Roussel(St. Jude Children's Research Hospital), Zhenmei Li(St. Jude Children's Research Hospital), Barbara Jonchère(St. Jude Children's Research Hospital), M. Brett Waddell(St. Jude Children's Research Hospital), R. Kiplin Guy(St. Jude Children's Research Hospital), Nancy E. Martinez(St. Jude Children's Research Hospital), Sergio C. Chai(St. Jude Children's Research Hospital), Liying Chi(St. Jude Children's Research Hospital), Jun J. Yang(St. Jude Children's Research Hospital), Rachelle R. Olsen(University of Utah), Kevin W. Freeman(University of Tennessee Health Science Center), Marie Morfouace(European Organisation for Research and Treatment of Cancer), Mi‐Kyung Yun(St. Jude Children's Research Hospital), Stephen W. White(St. Jude Children's Research Hospital), William R. Shadrick(St. Jude Children's Research Hospital), Anang A. Shelat(St. Jude Children's Research Hospital), Jonathan Low(St. Jude Children's Research Hospital), Jeanine E. Price(St. Jude Children's Research Hospital), Brandon Young(Avera Health), Daniel Savic(St. Jude Children's Research Hospital), Richard Lee(St. Jude Children's Research Hospital), Michele Connelly(St. Jude Children's Research Hospital), Lyudmila Tsurkan(St. Jude Children's Research Hospital), Taosheng Chen(St. Jude Children's Research Hospital)
Cancer Research
July 10, 2020
Cited by 43


Related Papers